News for Towa Pharmaceutical Co., Ltd. (4553.T)

Published at

Oct 25, 2023 4:40 PM

by globenewswire.com

mixed

mixed

Transdermal Drug Delivery System Market to Hit 4.3% CAGR with Transdermal Gels Segment Driving Growth During 2022–2030 | The Insight Partners

The global transdermal drug delivery system market revenue to reach USD 51.94 Billion by 2030....

VTRSV VTRS.MX VTRS VIA.DE NVSN.MX NVSEF NVSD.BA NVS NOVN.SW N1VS34.SA LYPHF JNJ HTSUF DJNJ3.BA DJNJ2.BA 4553.T 4530.T 2186.HK 0K9E.L UCBN.MX UCBJY UCBJF UCB.BR

Read more →
Published at

Aug 10, 2023 8:23 AM

by marketscreener.com

positive

positive

Towa Pharmaceutical : FY2023(1st quarter) Supplementary Material of Financial Results (1.03M/28P)

Stock Market Quotes and News : Equities, Indexes, Commodities, Forex on MarketScreener.com

4553.T

Read more →
Published at

Aug 10, 2023 8:23 AM

by marketscreener.com

neutral

neutral

Towa Pharmaceutical : FY2023(1st quarter) Summary of Consolidated Financial Results for the Three Months Ended June 30, 2023(Based on Japanese GAAP) (375K/7P)

Stock Market Quotes and News : Equities, Indexes, Commodities, Forex on MarketScreener.com

4553.T

Read more →
Published at

Dec 3, 2021 7:12 AM

by marketscreener.com

neutral

neutral

Chugai Pharmaceutical : Towa Pharmaceutical Receives Approval for Authorized Generic Version of Chugai's Osteoporosis Agent Edirol

Towa Pharmaceutical Receives Approval for Authorized Generic Version of Chugai's Osteoporosis Agent Edirol Chugai granted Towa... | December 3, 2021

CHGCY CHGCF 4553.T 4519.T

Read more →
Published at

Nov 11, 2021 8:44 PM

by prnewswire.com

neutral

neutral

Luye Pharma accorde à Zambon les droits exclusifs de commercialisation en Suisse de son traitement innovant contre la maladie d'Alzheimer, le Patch Transdermique Multi-Jours de Rivastigmine

/PRNewswire/ -- Le Luye Pharma Group (Luye Pharma) a annoncé aujourd'hui que sa filiale Luye Pharma Switzerland AG a conclu un accord avec Zambon Switzerland...

4553.T

Read more →
Published at

Nov 11, 2021 5:12 AM

by prnewswire.com

negative

negative

Luye Pharma gewährt Zambon exklusive Vermarktungsrechte in der Schweiz für sein innovatives Rivastigmin Mehrtages-Transdermalpflaster zur Behandlung der Alzheimer-Krankheit

/PRNewswire/ -- Die Luye Pharma Group (Luye Pharma) gab heute bekannt, dass ihre Tochtergesellschaft Luye Pharma Switzerland AG eine Vereinbarung mit Zambon...

4553.T

Read more →
Published at

Sep 23, 2021 9:12 AM

by marketscreener.com

positive

positive

Luye Pharma : Innovative Alzheimer's Disease Therapy Rivastigmine Multi-Day Transdermal Patch Receives Marketing Approval in the UK

Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Multi-Day Transdermal Patch has been granted by the UK's Medicines and Healthcare Products... | September 23, 2021

4553.T

Read more →

News for Towa Pharmaceutical Co., Ltd. (4553.T)

Transdermal Drug Delivery System Market to Hit 4.3% CAGR with Transdermal Gels Segment Driving Growth During 2022–2030 | The Insight Partners

Towa Pharmaceutical : FY2023(1st quarter) Supplementary Material of Financial Results (1.03M/28P)

Towa Pharmaceutical : FY2023(1st quarter) Summary of Consolidated Financial Results for the Three Months Ended June 30, 2023(Based on Japanese GAAP) (375K/7P)

Chugai Pharmaceutical : Towa Pharmaceutical Receives Approval for Authorized Generic Version of Chugai's Osteoporosis Agent Edirol

Luye Pharma accorde à Zambon les droits exclusifs de commercialisation en Suisse de son traitement innovant contre la maladie d'Alzheimer, le Patch Transdermique Multi-Jours de Rivastigmine

Luye Pharma gewährt Zambon exklusive Vermarktungsrechte in der Schweiz für sein innovatives Rivastigmin Mehrtages-Transdermalpflaster zur Behandlung der Alzheimer-Krankheit

Luye Pharma : Innovative Alzheimer's Disease Therapy Rivastigmine Multi-Day Transdermal Patch Receives Marketing Approval in the UK